Navigation Links
Data Demonstrates Long-Term Reduction In Seizure Frequency With Novel Once Daily Anti-Epileptic Zebinix(R)
Date:6/28/2009

S. MAMEDE DO CORONADO, Portugal, June 29 /PRNewswire/ -- Data presented today, in Budapest, demonstrated that add-on treatment with the novel, once-daily anti-epileptic Zebinix(R)* (eslicarbazepine acetate; ESL) resulted in a marked and sustained decrease in seizure frequency over the long-term(1).

Results from the one-year extension of a pivotal Eslicarbazepine Acetate phase III study were presented at the International Congress for Epilepsy in Budapest, Hungary. Patients not controlled with existing anti-epileptic drugs who were given eslicarbazepine acetate as an add-on treatment experienced a mean reduction in seizure frequency of more than 61% (95%CI: -68.2%, -55.5%)1. Nearly 65% of patients were classified as responders, meaning that they had achieved at least a 50% reduction in seizure frequency with Zebinix(R) treatment(1).

"These data continue to demonstrate the efficacy and safety of Zebinix(R) in the treatment of partial onset seizures", said Joyce Cramer, research scientist at Yale University School of Medicine, USA and President of The Epilepsy Therapy Project. "Epilepsy is a devastating condition that can be very difficult to manage and the availability of eslicarbazepine acetate adds an important new choice of therapy for patients who are in vital need of better seizure control."

Epilepsy is one of the most common neurological diseases, affecting approximately one in 100 people6. Treatment of partial-onset seizures, the most common type of epilepsy, remains a constant challenge and up to 40% of patients with partial seizures do not achieve seizure control with current anti-epileptics(2).

Additional studies presented at the IEC further reinforce the efficacy and safety of eslicarbazepine acetate in the treatment of partial-onset seizures, with or without secondary generalisation(3,4).

Pooled data from more than 1,000 patients enrolled in th
'/>"/>

SOURCE BIAL
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Study Demonstrates Efficacy of Pitavastatin in Elderly Patients
2. Semafores SF1126, a Vascular Targeted Pan-PI3K/mTOR Inhibitor, Is Well Tolerated and Demonstrates Activity in Phase I Solid Tumor Patients
3. Ongoing Landmark ROADMAP Study Demonstrates Significant Improvement in Blood Pressure Control at One Year, According to Blinded Results
4. Ground-Breaking Combination of All-Oral Agents Demonstrates Potential as Hepatitis C Treatment Regimen
5. ANA598 Demonstrates Potent Antiviral Activity at all Dose Levels in Completed Phase Ib Study in Hepatitis C Patients
6. Study Demonstrates Restylane(R) Effect Lasted 18 Months in 97% of Patients With One Repeat Injection
7. ANA598 Demonstrates Potent Antiviral Activity in an Early Clinical Study in HCV-Infected Patients
8. Study Demonstrates that AHCC(R) Enhances Immune System by Increasing the Production of Key Dendritic Cells
9. Video: Tasigna(R) Demonstrates Rapid Response as Initial Therapy in Life-Threatening Form of Leukemia
10. Arzerra(TM) (ofatumumab) Demonstrates High Response Rates in Patients With Fludarabine Refractory Chronic Lymphocytic Leukemia (CLL)
11. Thoratec Says Interim Data Analysis Demonstrates Statistical Superiority for the HeartMate II(R) in Destination Therapy Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/15/2009)... NEW YORK, Dec. 15 ... research report is available in its ... Instrument Manufacturing Industry in the U.S. ... Edition] ,, http://www.reportlinker.com/p0167745/Surgical-and-Medical-Instrument-Manufacturing-Industry-in-the-US-and-its-International-Trade-[Q4-2009-Edition].html ... of Surgical and Medical Instrument Manufacturing ...
(Date:12/15/2009)... NEW YORK, Dec. 15 ... research report is available in its ... - Drug Pipeline Analysis and Market ... http://www.reportlinker.com/p0167308/Systemic-Lupus-Erythematosus---Drug-Pipeline-Analysis-and-Market-Forecasts-to-2015.html ,, Systemic Lupus ... Market Forecasts to 2015 ,, ...
(Date:12/15/2009)... 15 Reportlinker.com announces that ... available in its catalogue: ,, ... of the competitive environment is unquestionably ... responsibilities, the task crucial to business ... factual competitive intelligence is vital to ...
Breaking Medicine Technology:Reportlinker Adds Surgical and Medical Instrument Manufacturing Industry in the U.S. and its International Trade [Q4 2009 Edition] 2Reportlinker Adds Surgical and Medical Instrument Manufacturing Industry in the U.S. and its International Trade [Q4 2009 Edition] 3Reportlinker Adds Surgical and Medical Instrument Manufacturing Industry in the U.S. and its International Trade [Q4 2009 Edition] 4Reportlinker Adds Surgical and Medical Instrument Manufacturing Industry in the U.S. and its International Trade [Q4 2009 Edition] 5Reportlinker Adds Surgical and Medical Instrument Manufacturing Industry in the U.S. and its International Trade [Q4 2009 Edition] 6Reportlinker Adds Surgical and Medical Instrument Manufacturing Industry in the U.S. and its International Trade [Q4 2009 Edition] 7Reportlinker Adds Surgical and Medical Instrument Manufacturing Industry in the U.S. and its International Trade [Q4 2009 Edition] 8Reportlinker Adds Systemic Lupus Erythematosus - Drug Pipeline Analysis and Market Forecasts to 2015 2Reportlinker Adds Systemic Lupus Erythematosus - Drug Pipeline Analysis and Market Forecasts to 2015 3Reportlinker Adds Systemic Lupus Erythematosus - Drug Pipeline Analysis and Market Forecasts to 2015 4Reportlinker Adds Systemic Lupus Erythematosus - Drug Pipeline Analysis and Market Forecasts to 2015 5Reportlinker Adds Systemic Lupus Erythematosus - Drug Pipeline Analysis and Market Forecasts to 2015 6Reportlinker Adds Systemic Lupus Erythematosus - Drug Pipeline Analysis and Market Forecasts to 2015 7Reportlinker Adds Systemic Lupus Erythematosus - Drug Pipeline Analysis and Market Forecasts to 2015 8Reportlinker Adds Top Ten World's Leading Orthopedics Companies 2Reportlinker Adds Top Ten World's Leading Orthopedics Companies 3Stemedica Selected by World Stem Cell Summit to Present Scientific Discoveries 55478 1Stemedica Selected by World Stem Cell Summit to Present Scientific Discoveries 55478 2Stemedica Selected by World Stem Cell Summit to Present Scientific Discoveries 55478 3MessageSolution Enterprise Email Archive Named Top Exchange Archiving Solution by Leading Exchange Site MSExchange org 55476 1MessageSolution Enterprise Email Archive Named Top Exchange Archiving Solution by Leading Exchange Site MSExchange org 55476 2MessageSolution Enterprise Email Archive Named Top Exchange Archiving Solution by Leading Exchange Site MSExchange org 55476 3MessageSolution Enterprise Email Archive Named Top Exchange Archiving Solution by Leading Exchange Site MSExchange org 55476 4MessageSolution Enterprise Email Archive Named Top Exchange Archiving Solution by Leading Exchange Site MSExchange org 55476 5Anesthetix Launches OPTIMETRIX 28TM 29 Perioperative Quality Management Tool 55473 1Anesthetix Launches OPTIMETRIX 28TM 29 Perioperative Quality Management Tool 55473 2Anesthetix Launches OPTIMETRIX 28TM 29 Perioperative Quality Management Tool 55473 3
... Remain on Schedule with Two Abstracts Accepted for ... Data Release in November 2008, BRIDGEWATER, N.J., ... company focused on the treatment of,cardiovascular and metabolic ... Jr. to the Company,s board of directors., ...
... Long term follow up results from chronically infected Hepatitis C,patients strongly confirm and ... first to show a statistically significant and long-term ... pave the way and strongly support move into a second generation, vaccine ... ...
Other Medicine Technology:Aegerion Pharmaceuticals, Inc. adds Peter Garrambone to Board of Directors, Secures Additional Capital for Clinical Trials 2Favourable Six Months Follow-Up Results From Intercell's Phase II Therapeutic Hepatitis C Program 2Favourable Six Months Follow-Up Results From Intercell's Phase II Therapeutic Hepatitis C Program 3Favourable Six Months Follow-Up Results From Intercell's Phase II Therapeutic Hepatitis C Program 4
(Date:12/15/2009)... -- Hosted by the Technology-based Learning SIG of ... 2009,s best eLearning designs. This year nominees, ... categories. The Venza Group entry, a highly ... hotelier, was selected as the winner of the ... by the panel of distinguished judges. While ...
(Date:12/15/2009)... CLARA, Calif., Dec. 15 Today, ... into Santa Clara County for the first ... Effective immediately, Coastal Healthcare Administrators will be ... by the Physicians Foundation for Medical Care. ... healthcare philosophy, Coastal maintains close working relationships ...
(Date:12/15/2009)... with hormones, but when the tumours start growing again ... thesis from the Sahlgrenska Academy, at the University of ... treatments for hormone-resistant prostate cancer. , Late in the ... spread, most patients are given hormone therapy. This reduces ... tumour shrinks. , "The problem is that the effect ...
(Date:12/15/2009)... A new study published by The University of ... for paid and unpaid work report higher average measures ... family models. , The ,shared roles, category, where each ... the total unpaid work, is a growing category that ... Couples are more likely to be in a shared ...
(Date:12/15/2009)... 2009) Although seen as a potential heart ... inhibiting activity of a transfer protein may not be ... Mayer USDA Human Nutrition Research Center on Aging (USDA ... of Medicine found an association between low plasma cholesterol ... heart disease in the Framingham Heart Study population. , ...
Breaking Medicine News(10 mins):Health News:The Venza Group Received Top Honors at the American Society of Training & Development (ASTD) eLearning Excellence Awards Ceremony Held on December 10, 2009 2Health News:Coastal Healthcare Administrators Expands Provider Network to Santa Clara County 2Health News:More blood vessels in hormone-resistant prostate tumors 2Health News:Low cholesterol transfer protein activity associated with heart disease risk 2
... was earlier thought that low-intensity laser treatment was ... of vision// from age-related macular degeneration (AMD). A ... Prevention Trial (CAPT) supported by grants from the ... of Health (NIH) has concluded that laser treatment ...
... find ways and means to slow down aging. Recent research ... extend life//. ,At the Wisconsin National Primate Research Center ... lugging a paunch and getting a face full of wrinkles. ... hooting at strangers, one of Matthias’s lab mates, Rudy, although ...
... Staphylococcus aureus infections may soon be overcome by a ... ,The team, receiving funds from the government, ... of the Staphylococcus aureus, in mice. This bacteria causes ... resistant to many antibiotics. ,Most hospital-acquired infections are ...
... which has sought to understand sexual behaviors has revealed, ... //in the present day are baseless and monogamy is ... survey are published in The Lancet. ,The ... that many had just a single recent sexual partner ...
... children's agency has launched the first online game in Kiswahili, ... Aids. ,The game is named as "What would ... scenarios so that he importance of prevention and testing is ... of young people do not know how to protect themselves ...
... to nature and tapped its endless resources for cures to ... mode, not surprising that// scientists have drawn upon the medicinal ... thousands of years and may even assist in the management ... diabetes. ,The herb named as Milk thistle also ...
Other Medicine News:Health News:People with early AMD not benefited by Laser Treatment 2Health News:Lesser Calories for Longer Life 2Health News:Vaccine may overcome Common Infections: Researchers 2Health News:Herbal Twist: Plausible Cure for Diabetes 'Crops' Up 2
... Brasseler USA™ MicroLine™ Small Bone Power ... operation while performing under the most ... system developed for small bone osteotomies ... Sagittal Saw (Extended Length Available), Oscillating ...
... Sagittal Saw, without hand throttle, ... Head rotates 360 deg. for ... our unique blade locking mechanism ... used with foot throttle (#6401-000), ...
Electric Reciprocating Saw, without throttle. Requires use of 6401-000 foot pedal along with an electric console. Can also be purchased with a hand throttle (#1915T)....
... contain rechargeable nickel cadmium battery cells. Heat ... battery life. Strict adherence to recommended autoclave ... recommendations will shorten battery life. Warning: Battery ... of the Battery Packs to autoclave conditions ...
Medicine Products: